• Country
    Clear
  • Thematic
    Clear
  • Type
  • Compatibility Level
  • Jurisdiction
3,509 Data sources

  • ES
  • NL
  • IT
  • Thematic: No

  • The Mitochondrial Disease Sequence Data Resource (MSeqDR) is a centralized genome and phenome bioinformatics resource built by the mitochondrial disease community to facilitate clinical diagnosis and research investigations of individual patient phenotypes, genomes, genes, and variants. It integrates community knowledge from expert‐curated databases with genomic and phenotype data shared by clinicians and researchers.

    more_vert
  • This repository provides open access to the work of staff and students of Universidad Europea. the interface is in Spanish and English.

    more_vert
  • more_vert
  • more_vert
  • PMut Data Repository collects predictions of the pathological effect of all possible single amino acid variants on Uniref Human protein sequences. Predictions were prepared using PMut 2017 predictor (2017 version).

    more_vert
  • APICURON is a database to credit and acknowledge the work of biocurators, it collects and aggregates biocuration events from third party resources and generates achievements and leaderboards.

    more_vert
  • more_vert
  • This site provides access to the research output of the institution. The interface is available in Spanish. Users may set up an RSS feed to be alerted to new content.

    more_vert
  • DSpace at IMDEA Networks is a digital repository for IMDEA Networks' research, including peer-reviewed articles, technical reports, theses, annual reports, and more.

    more_vert
  • Nearly 60% of patients undergoing cancer treatment are estimated to have had at least one potential drug-drug interaction; for patients receiving oral anticancer therapy, up to 50% have been reported to experience a potential drug-drug interaction, with 16% experiencing a major event. Drug-drug interactions are therefore a significant issue for cancer patients and the health care professionals who treat them. Combining the internationally recognised drug-drug interactions expertise of the University of Liverpool (UK) with the clinical pharmacology in oncology and haemotology expertise of Radboud University, Nijmegen (the Netherlands), this site was established in 2017 in response to the need for improved management of DDIs with anti-cancer agents.

    more_vert
  • chevron_left
  • 3
  • 4
  • 5
  • 6
  • 7
  • chevron_right
3,509 Data sources
  • The Mitochondrial Disease Sequence Data Resource (MSeqDR) is a centralized genome and phenome bioinformatics resource built by the mitochondrial disease community to facilitate clinical diagnosis and research investigations of individual patient phenotypes, genomes, genes, and variants. It integrates community knowledge from expert‐curated databases with genomic and phenotype data shared by clinicians and researchers.

    more_vert
  • This repository provides open access to the work of staff and students of Universidad Europea. the interface is in Spanish and English.

    more_vert
  • more_vert
  • more_vert
  • PMut Data Repository collects predictions of the pathological effect of all possible single amino acid variants on Uniref Human protein sequences. Predictions were prepared using PMut 2017 predictor (2017 version).

    more_vert
  • APICURON is a database to credit and acknowledge the work of biocurators, it collects and aggregates biocuration events from third party resources and generates achievements and leaderboards.

    more_vert
  • more_vert
  • This site provides access to the research output of the institution. The interface is available in Spanish. Users may set up an RSS feed to be alerted to new content.

    more_vert
  • DSpace at IMDEA Networks is a digital repository for IMDEA Networks' research, including peer-reviewed articles, technical reports, theses, annual reports, and more.

    more_vert
  • Nearly 60% of patients undergoing cancer treatment are estimated to have had at least one potential drug-drug interaction; for patients receiving oral anticancer therapy, up to 50% have been reported to experience a potential drug-drug interaction, with 16% experiencing a major event. Drug-drug interactions are therefore a significant issue for cancer patients and the health care professionals who treat them. Combining the internationally recognised drug-drug interactions expertise of the University of Liverpool (UK) with the clinical pharmacology in oncology and haemotology expertise of Radboud University, Nijmegen (the Netherlands), this site was established in 2017 in response to the need for improved management of DDIs with anti-cancer agents.

    more_vert
  • chevron_left
  • 3
  • 4
  • 5
  • 6
  • 7
  • chevron_right